India, Oct. 15 -- Fusion Antibodies plc (FAB.L), a clinical contract research organization (CRO), on Thursday discussed its financial results for the first half of the fiscal year 2027 ending September 30, 2026, at the Annual General Meeting, and noted lower-than-expected revenues attributed to difficult market conditions.
The company engineers antibodies and provides the same for preclinical testing involving antigen expression, purification, sequencing, antibody generation and humanization. The latter utilizes the proprietary CDRx platform.
H1 FY27 Financial Results Discussion:
Chairman Simon Douglas stated that the decline in half-yearly revenue to £0.46 million, compared to £0.84 million in the same period of 2025 was attri...